Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series

Table 1 Clinical and Treatment Characteristics of Eight Patients with Preexisting Cardiomyopathy Undergoing Anthracycline Chemotherapy for Any Cancer, With or Without the Cardioprotectant, Dexrazoxane

Patient #. sex; age, years	Cancer, Stage	Chemotherapy regimen; anthracycline, cumulative dose, mg/m²	Cardiac history	Before the start of anthracycline chemotherapy			LVEF, %, by time since anthracycline therapy
Patient #. sex; age, years	Cancer, Stage	Chemotherapy regimen; anthracycline, cumulative dose, mg/m²	Cardiac history	ACEi	Beta Blocker	Aldosterone Antagonist	Pre	During	Post	6 months post
Without dexrazoxane (controls)
1. M; 87	PTCL, IV	CHOP Doxorubicin, 300	NICM	Yes	Yes	Yes	45	–	10	–
2. M; 66	DLBCL, IV	R-EPOCH Doxorubicin, 120	Ischemic Cardiomyopathy	Yes	Yes	No	40	15	–	–
3. M; 65	AML, M4	Cytarabine + Daunorubicin Daunorubicin, 540	Chemotherapy- related cardiomyopathy	Yes	No	Yes	55	45	30	30
With dexrazoxane
4. F; 67^a	HL, IIIB	ABVD Doxorubicin, 300	NICM	Yes	Yes	No	35	35	35	25
5. F; 75	DLBCL, IIISE	CHOP Doxorubicin, 300	NICM	Yes	Yes	Yes	35	35	35	30
6. F 70	Ovarian, IV	Doxorubicin, 280	NICM	No	Yes	No	45	40	40	40
7. M; 73	NHL, IV	ABVD Doxorubicin, 300	Ischemic cardiomyopathy	Yes	Yes	Yes	40	40	40	40
8. F; 68	Breast, IV	Doxorubicin Doxorubicin, 300	NICM	Yes	Yes	No	40	40	40	35

LVEF left ventricular ejection fraction, ACEi angiotensin-converting enzyme inhibitors, DEX dexrazoxane, PTCL peripheral T-cell lymphoma, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, NICM non-ischemic cardiomyopathy, DLBCL diffuse large B-cell lymphoma, M4 acute myelomonocytic leukemia, R-EPOCH rituximab, etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin), AML acute myeloid leukemia, ABVD Adriamycin (doxorubicin), Bleomycin, Vinblastine, Dacarbazine, HL Hodgkin lymphoma
^aPatient had a defibrillator before chemotherapy

ISSN: 2057-3804